-
Start Preamble
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is postponing the meeting of the Arthritis Advisory Committee scheduled for March 17, 2015. The meeting was announced in the Federal Register of February 10, 2015 (80 FR 7480). The postponement is due to information requests pending with the sponsor of the application. A future meeting date will be announced in the Federal Register.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Stephanie L. Begansky, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, email: AAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.
Start SignatureDated: March 6, 2015.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2015-05527 Filed 3-10-15; 8:45 am]
BILLING CODE 4164-01-P
Document Information
- Published:
- 03/11/2015
- Department:
- Food and Drug Administration
- Entry Type:
- Notice
- Action:
- Notice.
- Document Number:
- 2015-05527
- Pages:
- 12823-12823 (1 pages)
- Docket Numbers:
- Docket No. FDA-2015-N-0001
- PDF File:
- 2015-05527.pdf
- Supporting Documents:
- » Attachment 3 Neurovascular Quality Initiative List of Devices re: Comment from M2S, Inc.
- » Attachment 2 Neurovascular Quality initiative 2015 Procedure Inclusion/Exclusion Criteria re: Comment from M2S, Inc.
- » Transcript of the March 30-31, 2015 Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT) III Workshop on Inflammatory Bowel Disease, Day 2
- » Transcript of the March 30-31, 2015 Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics (GREAT) III Workshop on Inflammatory Bowel Disease, Day 1